60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP – Free Report) – Analysts at HC Wainwright increased their Q3 2024 earnings estimates for shares of 60 Degrees Pharmaceuticals in a research report issued on Thursday, August 15th. HC Wainwright analyst E. White now expects that the company will earn ($0.93) per share for the quarter, up from their previous estimate of ($1.44). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for 60 Degrees Pharmaceuticals’ current full-year earnings is ($6.72) per share. HC Wainwright also issued estimates for 60 Degrees Pharmaceuticals’ Q4 2024 earnings at ($0.97) EPS, FY2024 earnings at ($5.43) EPS, FY2025 earnings at ($0.68) EPS and FY2026 earnings at ($0.23) EPS.
60 Degrees Pharmaceuticals (NASDAQ:SXTP – Get Free Report) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($4.23) EPS for the quarter, missing analysts’ consensus estimates of ($2.79) by ($1.44). The firm had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $0.11 million.
60 Degrees Pharmaceuticals Trading Up 1.3 %
60 Degrees Pharmaceuticals Company Profile
60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.
Recommended Stories
- Five stocks we like better than 60 Degrees Pharmaceuticals
- How Investors Can Find the Best Cheap Dividend Stocks
- Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
- Why Are Stock Sectors Important to Successful Investing?
- 2 Option Strategies to Maximize Profits in a Bear Market
- Most Volatile Stocks, What Investors Need to Know
- Lululemon Stock Gears Up for a Massive Comeback Rally
Receive News & Ratings for 60 Degrees Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 60 Degrees Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.